Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Metabolic |
| Evidence grade | Strong |
| Also known as | Mounjaro, Zepbound |
| Mechanism | Activates both GIP and GLP-1 receptors. The added GIP activity appears to improve insulin sensitivity and lipid handling while blunting some of the nausea associated with pure GLP-1 agonism. |
| Key benefits | Up to ~21% mean weight loss at 15 mg in SURMOUNT-1 · Superior HbA1c reduction versus semaglutide in head-to-head trials · Improvements in sleep apnoea and blood pressure |
| Side effects | Nausea · Decreased appetite to the point of undereating · Diarrhoea · Rare pancreatitis |
| Half-life | About 5 days |
| Administration | Once-weekly subcutaneous injection |
| Dosing overview | 2.5 mg weekly starting dose, escalating in 2.5 mg steps up to 15 mg |
| Storage | Refrigerated pens; can be at room temperature for up to 21 days per label |
| Legal status | FDA-approved and prescription-only. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.